Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)-Reference-Cited by-同舟云学术

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Published:2022-09-10 Issue:13 Volume:63 Page:3232-3236
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ball Brian J.¹^ORCID,Arslan Shukaib¹,Koller Paul¹,Ngo Dat¹,Afkhami Michelle¹,Salhotra Amandeep¹^ORCID,Al-Malki Monzr¹^ORCID,Aribi Ahmed¹,Ali Haris¹,Sandhu Karamjeet¹,Otoukesh Salman¹,Amanam Idoroenyi¹^ORCID,Pourhassan Hoda¹^ORCID,Artz Andrew¹^ORCID,Curtin Peter¹,Stein Anthony¹,Nakamura Ryotaro¹^ORCID,Marcucci Guido¹^ORCID,Smith Eileen¹,Pullarkat Vinod¹^ORCID,Aldoss Ibrahim¹^ORCID

Affiliation:

1. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA

Funder

the National Institute of Health K12

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2116934

Reference11 articles.

1. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A